{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:07:53Z","timestamp":1767827273050,"version":"3.49.0"},"reference-count":106,"publisher":"Oxford University Press (OUP)","issue":"25","license":[{"start":{"date-parts":[[2017,12,9]],"date-time":"2017-12-09T00:00:00Z","timestamp":1512777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"DOI":"10.1093\/eurheartj\/ehx668","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T20:13:31Z","timestamp":1511208811000},"page":"2368-2375","source":"Crossref","is-referenced-by-count":35,"title":["Cardioprotective anti-hyperglycaemic medications: a review of clinical trials"],"prefix":"10.1093","volume":"39","author":[{"given":"Haitham M","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Ave, Desk JB1 Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitham","family":"Khraishah","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, 330 Brookline Ave Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Ave, Desk JB1 Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,12,9]]},"reference":[{"key":"key\n\t\t\t\t20180701045800_ehx668-B1","author":"International Diabetes Federation","year":"2014"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Emerging Risk Factors Collaboration","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B3","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","article-title":"Intensive insulin therapy prevents the progression of diabetic microvascular complications in japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study","volume":"28","author":"Ohkubo","year":"1995","journal-title":"Diabetes Res Clin Pract"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B5","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"ADVANCE Collaborative Group","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jacc.2008.10.008","article-title":"Intensive glycemic control and the prevention of cardiovascular events: implications of the accord, advance, and va diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College Of Cardiology Foundation and the American Heart Association","volume":"53","author":"Skyler","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B7","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"ACCORD Study Group","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B8","doi-asserted-by":"crossref","first-page":"34i","DOI":"10.1016\/j.amjcard.2007.03.004","article-title":"Glycemia treatment strategies in the action to control cardiovascular risk in diabetes (ACCORD) trial","volume":"99","author":"Gerstein","year":"2007","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B9","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2337\/dc12-0719","article-title":"Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease","volume":"36","author":"Hong","year":"2013","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B11","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B12","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B14","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B15","author":"UFaD Administration","year":"2008"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B16","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMp1309610","article-title":"The cardiovascular safety of diabetes drugs\u2013insights from the rosiglitazone experience","volume":"369","author":"Hiatt","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B17","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.294.20.joc50147","article-title":"Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus","volume":"294","author":"Nissen","year":"2005","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B18","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","article-title":"Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes","volume":"36","author":"Ferrannini","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/1871525714666151106121215","article-title":"A review of sodium glucose co-transporter 2 inhibitors canagliflozin, dapagliflozin and empagliflozin","volume":"13","author":"Syed","year":"2015","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.2040-1124.2012.00227.x","article-title":"Role of sodium-glucose transporters in glucose uptake of the intestine and kidney","volume":"3","author":"Harada","year":"2012","journal-title":"J Diabetes Investig"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B22","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter sglt2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B23","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B24","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.amjcard.2017.05.015","article-title":"Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes","volume":"120","author":"Paneni","year":"2017","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B25","author":"ClinicalTrials.gov","year":"2017"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B26","author":"ClinicalTrials.gov","year":"2017"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B27","author":"ClinicalTrials.gov","year":"2017"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B28","author":"ClinicalTrials.gov","year":"2016"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B29","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","article-title":"Adverse effects and safety of sglt-2 inhibitors","volume":"40","author":"Halimi","year":"2014","journal-title":"Diabetes Metab"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijcard.2016.11.181","article-title":"Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type ii diabetes mellitus: a meta-analysis of placebo-controlled randomized trials","volume":"228","author":"Saad","year":"2017","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B31","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B32","author":"UFaD Administration","year":"2016"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B33","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease","author":"Wanner","year":"2017","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B34","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the empa-reg outcome\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B35","article-title":"Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the empa-reg outcome\u00ae trial","author":"Fitchett","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B36","author":"ClinicalTrials.gov","year":"2017"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B37","author":"ClinicalTrials.gov","year":"2017"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the cvd-real study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (cvd-real nordic): a multinational observational analysis","volume":"5","author":"Birkeland","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B40","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: Glp-1 and gip","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1900\/RDS.2011.8.293","article-title":"Physiology of incretins in health and disease","volume":"8","author":"Deacon","year":"2011","journal-title":"Rev Diabet Stud"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B42","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S1262-3636(08)73397-4","article-title":"Physiology of incretins (gip and glp-1) and abnormalities in type 2 diabetes","volume":"34","author":"Gautier","year":"2008","journal-title":"Diabetes Metab"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B43","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1345\/aph.1Q024","article-title":"Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"45","author":"Pinelli","year":"2011","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B44","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B45","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2011-0599","article-title":"The safety of incretin-based therapies\u2013review of the scientific evidence","volume":"96","author":"Drucker","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2015.09.010","article-title":"Basal and stimulated calcitonin levels in patients with type 2 diabetes did not change during 1 year of liraglutide treatment","volume":"65","author":"Lunati","year":"2016","journal-title":"Metabolism"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B47","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/db09-0626","article-title":"Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice","volume":"58","author":"Koehler","year":"2009","journal-title":"Diabetes"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B48","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2337\/dc08-1755","article-title":"Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study","volume":"32","author":"Noel","year":"2009","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B49","doi-asserted-by":"crossref","first-page":"120.","DOI":"10.1007\/s11892-016-0823-6","article-title":"A plethora of glp-1 agonists: decisions about what to use and when","volume":"16","author":"Samson","year":"2016","journal-title":"Curr Diab Rep"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B50","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B51","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/jch.12425","article-title":"Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus","volume":"16","author":"Weir","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B52","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.diabres.2016.09.016","article-title":"Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: focus on sglt2 inhibitors and empa-reg outcome","volume":"121","author":"Scheen","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B53","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B54","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1600175","article-title":"Blood-pressure lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Lonn","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B55","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of sglt2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B56","doi-asserted-by":"crossref","first-page":"939.","DOI":"10.1001\/jamacardio.2017.1891","article-title":"The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure","volume":"2","author":"Verma","year":"2017","journal-title":"JAMA Cardiol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B57","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B58","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus","volume":"4","author":"Heise","year":"2013","journal-title":"Diabetes Ther"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B59","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.jacc.2016.08.070","article-title":"A test in context: hemoglobin A1c and cardiovascular disease","volume":"68","author":"Gore","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B60","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejps.2016.08.025","article-title":"Sodium glucose cotransporter 2 (SGLT2) inhibitors: current status and future perspective","volume":"93","author":"Madaan","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B61","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc15-2688","article-title":"Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes","volume":"39","author":"Daniele","year":"2016","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2015.11.026","article-title":"Uric acid in metabolic syndrome: from an innocent bystander to a central player","volume":"29","author":"Kanbay","year":"2016","journal-title":"Eur J Intern Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B63","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B64","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B65","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-physiol-020911-153333","article-title":"Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney","volume":"74","author":"Vallon","year":"2012","journal-title":"Annu Rev Physiol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B66","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00125-009-1268-0","article-title":"Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis","volume":"52","author":"Magee","year":"2009","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B67","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B68","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B69","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B70","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.2337\/dc16-1312","article-title":"Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the empa-reg outcome trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B71","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2013060588","article-title":"Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on na+\/h+ exchanger isoform 3 activity in the renal proximal tubule","volume":"25","author":"Pessoa","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B72","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1152\/ajpregu.00127.2011","article-title":"Increased nhe3 abundance and transport activity in renal proximal tubule of rats with heart failure","volume":"302","author":"Inoue","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B73","doi-asserted-by":"crossref","first-page":"1025.","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B74","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCRESAHA.108.175141","article-title":"Activation of na+\/h+ exchanger 1 is sufficient to generate ca2+ signals that induce cardiac hypertrophy and heart failure","volume":"103","author":"Nakamura","year":"2008","journal-title":"Circ Res"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B75","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic na+ through inhibition of the cardiac na+\/h+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B76","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"Cv protection in the empa-reg outcome trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B77","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","article-title":"Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis","volume":"35","author":"Kaptoge","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B78","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.2174\/13816128113196660748","article-title":"Enos uncoupling in cardiovascular diseases\u2013the role of oxidative stress and inflammation","volume":"20","author":"Karbach","year":"2017","journal-title":"Curr Pharm Des"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B79","doi-asserted-by":"crossref","first-page":"e112394.","DOI":"10.1371\/journal.pone.0112394","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity","volume":"9","author":"Oelze","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B80","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B81","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diabet.2015.02.003","article-title":"Antidiabetic agents: potential anti-inflammatory activity beyond glucose control","volume":"41","author":"Scheen","year":"2015","journal-title":"Diabetes Metab"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B82","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","article-title":"Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome","volume":"15","author":"Kusaka","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B83","doi-asserted-by":"crossref","first-page":"229.","DOI":"10.1186\/s12872-017-0663-6","article-title":"Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study","volume":"17","author":"Brown","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B84","doi-asserted-by":"crossref","first-page":"e014728.","DOI":"10.1136\/bmjopen-2016-014728","article-title":"The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial","volume":"7","author":"Larsen","year":"2017","journal-title":"BMJ Open"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B85","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B86","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B87","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B88","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/er.2011-1052","article-title":"Cardiovascular biology of the incretin system","volume":"33","author":"Ussher","year":"2012","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B89","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.atherosclerosis.2012.09.012","article-title":"An emerging role of dipeptidyl peptidase 4 (dpp4) beyond glucose control: potential implications in cardiovascular disease","volume":"226","author":"Zhong","year":"2013","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B90","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00395-015-0465-x","article-title":"Gliptin and glp-1 analog treatment improves survival and vascular inflammation\/dysfunction in animals with lipopolysaccharide-induced endotoxemia","volume":"110","author":"Steven","year":"2015","journal-title":"Basic Res Cardiol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B91","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/dom.12750","article-title":"Vascular effects of linagliptin in non-obese diabetic mice are glucose-independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)\/caveolin-1 (CAV-1) pathway","volume":"18","author":"Vellecco","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B92","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/dom.12641","article-title":"Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor","volume":"18","author":"Darsalia","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B93","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B94","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1499-2671(09)33072-5","article-title":"Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis","volume":"33","author":"Plutzky","year":"2009","journal-title":"Can J Diabetes"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B95","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (lead-4 met+tzd)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B96","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc13-2618","article-title":"Simultaneous glp-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes","volume":"37","author":"Ceriello","year":"2014","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B97","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00125-011-2297-z","article-title":"Glucagon-like peptide-1 (glp-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology","volume":"54","author":"Drucker","year":"2011","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B98","article-title":"Gliptins suppress inflammatory macrophage activation to mitigate inflammation, fibrosis, oxidative stress, and vascular dysfunction in models of nonalcoholic steatohepatitis and liver fibrosis","author":"Wang","year":"2017","journal-title":"Antioxid Redox Signal"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B99","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.amjmed.2017.03.010","article-title":"Glp-1 levels predict mortality in patients with critical illness as well as end-stage renal disease","volume":"130","author":"Lebherz","year":"2017","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B100","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cvr\/cvs246","article-title":"Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition","volume":"96","author":"Kr\u00f6ller-Sch\u00f6n","year":"2012","journal-title":"Cardiovasc Res"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B101","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with st-segment elevation myocardial infarction","volume":"33","author":"L\u00f8nborg","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B102","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/ATVBAHA.113.301586","article-title":"Cardioprotective effects of exenatide in patients with st-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study","volume":"33","author":"Woo","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B103","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ahj.2015.07.014","article-title":"Effects of liraglutide on left ventricular function in patients with st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"170","author":"Chen","year":"2015","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B104","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"key":"key\n\t\t\t\t20180701045800_ehx668-B106","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/bph.13549","article-title":"Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice","volume":"174","author":"Steven","year":"2017","journal-title":"Br J Pharmacol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/39\/25\/2368\/25103015\/ehx668.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T10:54:13Z","timestamp":1570359253000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/39\/25\/2368\/4718126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,9]]},"references-count":106,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2017,12,9]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehx668","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7,1]]},"published":{"date-parts":[[2017,12,9]]}}}